Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE VALERATE versus UCERIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE VALERATE versus UCERIS.
HYDROCORTISONE VALERATE vs UCERIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects.
Uceris (budesonide) is a corticosteroid with potent glucocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines (e.g., IL-1, IL-2, IL-4, IL-5, TNF-alpha), suppression of arachidonic acid metabolism via phospholipase A2 inhibition, and reduction of inflammatory cell infiltration. It has high topical anti-inflammatory activity and undergoes extensive first-pass hepatic metabolism, minimizing systemic bioavailability.
Apply a thin film to affected area twice daily. Topical use only.
For induction of remission in mild to moderate active ulcerative colitis: one 9 mg extended-release tablet orally once daily for up to 8 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours for the parent drug; 18-36 hours for the active metabolites (clinical context: duration of action is prolonged due to local tissue retention and metabolite activity)
2.8-4.5 hours (terminal). Clinical context: short half-life supports once-daily extended-release formulation for colonic delivery.
Renal (approximately 80% as metabolites, <1% unchanged), fecal/biliary (approximately 20% as metabolites)
Renal: <1%. Fecal: approximately 63% as budesonide and metabolites. Biliary: minor.
Category D/X
Category C
Corticosteroid
Corticosteroid